
Publication
Strategic asset search and evaluation in biopharma
Biotechnology companies are primarily built around platform technologies and focused on asset specific value creation.
United States | Publication | December 2023
The M&A Journal recently spoke with Global Head of Corporate, M&A and Securities Ayse Yüksel Mahfoud to discuss the Global M&A Trends and Risks.
Read The M&A Journal article, “A study from Norton Rose Fulbright sees green shoots amid the challenges.”
Publication
Biotechnology companies are primarily built around platform technologies and focused on asset specific value creation.
Subscribe and stay up to date with the latest legal news, information and events . . .
© Norton Rose Fulbright US LLP 2025